When was Sironax founded?

Sironax was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is Sironax located?

Sironax is headquartered in Changping District, China.

How many employees does Sironax have?

As of Sep 30, 2026, the latest employee count at Sironax is 70.

Is Sironax a funded company?

Sironax is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Aug 02, 2022.

When was the latest funding round of Sironax?

Sironax's latest funding was a $***** Series B round on Aug 02, 2022, with participation from 14 investors.

Where does Sironax rank among its competitors?

Sironax ranks 56th amongst 458 active competitors, of which 161 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Sironax?

Sironax's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Among them, Alchemab secured the most recent funding round in July, 2026.

Sironax - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for inflammatory and neurodegenerative diseases. The company is focusing on the development of small molecular compounds for targeting cell death signaling pathways. The company has a portfolio of drugs for inflammatory bowel disease, acute kidney injury, Alzheimer's, and multiple sclerosis.

Website: sironax.com
Email ID: *****@sironax.com
Phone Number: +86 **********

Key Metrics

Founded Year

2017

Location

Changping District, China

Stage

Series B

Total Funding

$200M in 1 round

Latest Funding Round

Series B, Aug 02, 2022, $*****

Investors

Yunfeng Capital & 15 more

Ranked

56^th among 458 active competitors

Employee Count

70 as on Sep 30, 2026

Similar Companies

Denali Therapeutics & 568 more

View Sironax's full profile

Sironax has raised a total funding of $200M over 1 round. Its latest funding round was a Series B round on Aug 02, 2022 for $*****. 14 investors participated in its latest round. Sironax has 16 institutional investors.

Here is the list of recent funding rounds of Sironax:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 02, 2022	2491920	Series B	6051875	3968014	2468835	8547982

Access funding benchmarks and valuations. Sign up today!

View details of Sironax's funding rounds and investors

The founders of Sironax are Zhiyuan Zhang and Xiaodong Wang.

Here are the details of Sironax's key team members:

Zhiyuan Zhang: Co-Founder of Sironax.
Contact Info: 1 email address
Xiaodong Wang: Co-Founder of Sironax.
Contact Info: 1 email address

View details of Sironax's Founder profiles and Board Members

Sironax's employee count trend

Sironax has 70 employees as of Sep 26. Here is Sironax's employee count trend over the years:

Uncover Sironax's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sironax include Denali Therapeutics, Fulcrum Therapeutics and Annexon. Here is the list of Top 10 competitors of Sironax, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	70/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
4th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	64/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
56th	Sironax 2017, Changping District (China), Series B	Developer of drugs for inflammatory and neurodegenerative diseases	$200M	Temasek, Yunfeng Capital & 14 others	55/100